JETEMA, Co., Ltd.

KOSDAQ 216080.KQ

JETEMA, Co., Ltd. EBITDA Margin for the year ending December 31, 2023: 38.08%

JETEMA, Co., Ltd. EBITDA Margin is 38.08% for the year ending December 31, 2023, a 3.65% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • JETEMA, Co., Ltd. EBITDA Margin for the year ending December 31, 2022 was 36.74%, a -31.93% change year over year.
  • JETEMA, Co., Ltd. EBITDA Margin for the year ending December 31, 2021 was 53.97%, a 318.24% change year over year.
  • JETEMA, Co., Ltd. EBITDA Margin for the year ending December 31, 2020 was -24.73%, a 63.94% change year over year.
  • JETEMA, Co., Ltd. EBITDA Margin for the year ending December 31, 2019 was -68.59%, a 43.07% change year over year.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
KOSDAQ: 216080.KQ

JETEMA, Co., Ltd.

CEO Jeong Sun Nam
IPO Date Nov. 14, 2019
Location South Korea
Headquarters 1283-4, Gagok-ri
Employees 227
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

JETEMA, Co., Ltd., a bio venture company, engages in the research and development of medicines and medical devices. It offers botulinum toxins, fillers, anti-aging solutions, lifting threads for medical treatment, laser surgical instruments, and skin care hyaluronic acid masks. The company is headquartered in Wonju, South Korea.

StockViz Staff

January 15, 2025

Any question? Send us an email